Page 61 - 《南京医科大学学报(自然科学版)》2025年第9期
P. 61
第45卷第9期 杨继辰,邱 玲,林建国. 监测免疫治疗反应的颗粒酶B靶向分子影像探针研究进展[J].
2025年9月 南京医科大学学报(自然科学版),2025,45(9):1267-1275 ·1273 ·
表1 靶向颗粒酶B的分子影像探针总结
Table 1 Summary of molecular imaging probes targeting granzyme B
Imaging mode Probe name Probe property Experimental model Research stage
PET 68 Ga⁃NOTA⁃GZP Mouse⁃derived CT26 Preclinical [24]
68 [28]
PET Ga⁃grazytracer Human⁃derived MC38,4T1 PhaseⅠ/Ⅱ clinical trial
68
PET [ Ga]Ga⁃NOTA⁃GSI Mouse⁃derived B16⁃F10 PhaseⅠ/Ⅱ clinical trial [32]
18
PET [ F]SF⁃M⁃14 Mouse⁃derived 4T1 Preclinical [34]
18
PET [ F]SF⁃H⁃14 Human⁃derived 4T1 Preclinical [34]
18
PET [ F]AlF⁃mNOTA⁃GZP Mouse⁃derived MC38,CT26 Preclinical [40]
PET 64 Cu⁃GRIP B Human⁃derived MC38,CT26 Clinical trial [42]
[43]
NIRF GNR Human⁃derived MC38,B16⁃F10 Preclinical
[44]
NIRF CyGbPF Mouse⁃derived 4T1 Preclinical
[44]
NIRF CyGbPP Human⁃derived 4T1 Preclinical
NIRF G⁃SNAT⁃Cy5 Mouse⁃derived CT26 Preclinical [45]
NIRF Cy5.5⁃CBT⁃NPs Mouse⁃derived B16⁃OVA Preclinical [22]
NIRF H5 Human⁃derived E0771 Preclinical [46]
[48]
CL 1 Human⁃derived MDA⁃MB⁃231 Preclinical
[51]
BL GBLI⁃2 Mouse⁃derived CT26⁃Luc Preclinical
[52]
NIRF/PA SPNP Mouse⁃derived 4T1 Preclinical
利益冲突声明: 947-953
所有作者声明无利益冲突。 [3] PARDOLL D M. The blockade of immune checkpoints in
Conflict of Interests: cancer immunotherapy[J]. Nat Rev Cancer,2012,12
All authors declare no conflict of interests. (4):252-264
作者贡献声明: [4] RIBAS A,WOLCHOK J D. Cancer immunotherapy using
杨继辰负责文献检索、资料的收集分析以及文章的整体 checkpoint blockade[J]. Science,2018,359(6382):
构思与写作,并根据修改意见进行修订。邱玲参与综述手稿 1350-1355
的修订与校稿,对文章的知识性内容作批评性审阅。林建国 [5] CHEN L P,HAN X. Anti⁃PD⁃1/PD⁃L1 therapy of human
负责文章的构思设计与手稿修订,提供资金支持并承担监督 cancer:past,present,and future[J]. J Clin Invest,2015,
工作。 125(9):3384-3391
Author’s Contributions: [6] 张 虎,毛春蓉,练 云,等. 一种新型结直肠癌预后模
型的建立与治疗预测[J]. 南京医科大学学报(自然科
YANG Jichen was responsible for literature retrieval,data
collection,conception,writing,and revision. QIU Ling partici⁃ 学版),2024,44(9):1217-1226
pated in the critical review,editing,revision,and proofreading. ZHANG H,MAO C R,LIAN Y,et al. Establishment and
treatment prediction of a new prognostic model for colorec⁃
LIN Jianguo was responsible for conception,revision,financial
support,and supervision. tal cancer[J]. Journal of Nanjing Medical University(Nat⁃
ural Sciences),2024,44(9):1217-1226
[参考文献]
[7] 许杨悦,胡 蒙,武常玲,等. 真实世界中肺癌免疫检查
[1] AMGHEIB A,FU R S,ABOAGYE E O. Positron emission 点抑制剂治疗的安全性及有效性[J]. 南京医科大学学
tomography probes for imaging cytotoxic immune cells[J]. 报(自然科学版),2023,43(12):1668-1674
Pharmaceutics,2022,14(10):2040 XU Y Y,HU M,WU C L,et al. Safety and efficacy of
[2] 魏艳秋,季辰菲,孙 伟,等. 肺癌合并免疫检查点抑制 immune checkpoint inhibitors for lung cancer in the real
剂相关肺炎的临床特征和预后分析[J]. 南京医科大学 world[J]. Journal of Nanjing Medical University(Natural
学报(自然科学版),2024,44(7):947-953 Sciences),2023,43(12):1668-1674
WEI Y Q,Ji C F,SUN W,et al. Clinical characteristics [8] NISHINO M,RAMAIYA N H,HATABU H,et al. Moni⁃
and prognosis of lung cancer with immune checkpoint toring immune⁃checkpoint blockade:response evaluation
inhibitor ⁃ associated pneumonia[J]. Journal of Nanjing and biomarker development[J]. Nat Rev Clin Oncol,
Medical University(Natural Sciences),2024,44(7): 2017,14(11):655-668

